Clinical trials · Chicago, IL
Allergy clinical trials in Chicago
We’re tracking 26 recruiting allergy studies with a site in or near Chicago — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Chicago
- NCT07040319RecruitingPhase 1/Phase 2
Hepatitis C treatment study for pregnant women
This study tests a medicine called glecaprevir/pibrentasvir for pregnant women with hepatitis C, with or without HIV. It aims to see how the medicine works in the body and if it is safe during pregnancy.
Chicago, IllinoisAges 16–45 - NCT06517693RecruitingPhase 1
HIV antibody safety study for newborns at risk
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
Chicago, IllinoisAges Up to 3 days - NCT05285891RecruitingPhase 4
Stopping ocrelizumab in early relapsing multiple sclerosis
This study looks at whether people with early relapsing multiple sclerosis can safely stop ocrelizumab. Researchers will compare health and MRI findings over time to see if stopping helps or increases relapse risk.
Chicago, IllinoisAges 18–55 - NCT06970977Recruiting
Chronic sinusitis questionnaire validation study
This study is testing a new questionnaire to better understand chronic sinusitis symptoms. It may help improve how doctors diagnose and treat the condition.
Chicago, IllinoisAges 18 years+ - NCT07342491RecruitingPhase 1
Testing dasatinib to shrink HIV reservoir
This trial tests whether the drug dasatinib can reduce the hidden HIV reservoir in people who have had their virus well-controlled on HIV medications for a long time. It may help move toward a cure by targeting the cells where HIV hides.
Chicago, IllinoisAges 18 years+ - NCT06918990RecruitingPhase 1
CarBel for antibody-mediated rejection after kidney transplant
This study tests a new drug called CarBel to treat antibody-mediated rejection in kidney transplant patients. The goal is to see if it can help stop the rejection and protect your new kidney.
Chicago, IllinoisAges 18–75 - NCT01186913Enrolling by invitation
Natural history study for severe combined immune deficiency (SCID)
This study follows children and adults with SCID and related immune disorders to understand how the illness behaves over time. It also helps researchers learn which testing results and genetic types of SCID match different treatment plans.
Chicago, IllinoisAges Any age - NCT06136091Recruiting
Asthma study in select communities using a smartphone app
This study looks at how asthma affects people in certain communities and tests a new way to manage it using a smartphone app. It is for people with long-standing asthma and those without asthma, to compare their health over time.
Chicago, IllinoisAges 6–17 - NCT05947071RecruitingPhase 2
Higher-dose flu vaccine versus standard dose in child transplant patients
This trial compares a higher-dose flu vaccine to the standard dose in children who recently received a kidney, heart, and/or liver transplant. It aims to see which dose better protects children against influenza while checking for safety.
Chicago, IllinoisAges 3–17 - NCT06055608RecruitingPhase 2
Improving kidney transplant outcomes in teens and young adults
This trial tests a new approach to help teenagers and young adults keep their first kidney transplant working well. It looks at how to improve long-term success by carefully managing the immune system around the time of transplant.
Chicago, IllinoisAges 13–20 - NCT05719441RecruitingPhase 2
Antibodies plus early HIV treatment to try for HIV remission
This study tests whether giving special HIV-fighting antibodies along with starting standard HIV medicine soon after infection can help you reach “HIV remission.” It may reduce or delay the return of detectable virus, but you must be willing to follow close monitoring and specific study steps.
Chicago, IllinoisAges 18–70 - NCT06280950RecruitingPhase 2
Reducing immune-suppressing drugs after liver transplant with everolimus
This study tests if adding everolimus can allow liver transplant recipients to safely reduce their usual immune-suppressing medicines. It aims to protect kidney function while preventing organ rejection.
Chicago, IllinoisAges 18 years+ - NCT07549503RecruitingPhase 2
Liver Transplant Immune Changes Study
This research study tracks early signs of immune system changes in children who received a liver transplant 3–7 years ago and are doing well. By studying blood and liver samples, researchers hope to better understand how to prevent rejection and improve long-term transplant survival.
Chicago, IllinoisAges 3–13 - NCT07108387RecruitingPhase 2
Stopping or reducing tocilizumab for well-controlled giant cell arteritis
This study compares stopping tocilizumab (Actemra) completely versus reducing the dose in people whose giant cell arteritis has been well controlled for at least a year. The goal is to find out which approach keeps the disease in remission while reducing medication side effects.
Chicago, IllinoisAges 50 years+ - NCT07059091RecruitingPhase 2
Omalizumab for COPD with allergies
This trial tests if omalizumab, an allergy medication, can help people with COPD who have allergies to common indoor triggers like cat, dog, mouse, cockroach, or dust mite. It aims to reduce flare-ups and improve breathing.
Chicago, IllinoisAges 40 years+ - NCT05201469RecruitingPhase 2
VIB4920 for lupus kidney inflammation not responding well enough
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
Chicago, IllinoisAges 18 years+ - NCT07103746RecruitingPhase 2
Ublituximab for antibody-positive IMNM
This study tests an investigational medication called ublituximab (an infusion) for people with a rare autoimmune muscle disease called IMNM. It aims to reduce muscle weakness and damage by targeting specific immune cells (B cells). To join, you need a recent diagnosis (within 1 year), specific antibodies, and be on limited other medications.
Chicago, IllinoisAges 18 years+ - NCT06075745RecruitingPhase 2
CMV Vaccine Study for Liver Transplant Candidates
This trial tests a vaccine to prevent cytomegalovirus (CMV) infection in people awaiting a first liver transplant. You may be eligible if you have never been infected with CMV and are scheduled to receive a liver transplant within the next 1 to 12 months.
Chicago, IllinoisAges 18 years+ - NCT02140255RecruitingPhase 1/Phase 2
Intensive early HIV treatment in newborns to aim for remission
This study gives very early, intensive HIV medicine to infants diagnosed with HIV and follows them closely to see if HIV can go into remission (stop being detectable without ongoing treatment). It may help families understand whether treating right after birth can change a child’s long-term HIV outlook.
Chicago, IllinoisAges Up to 2 days - NCT05272241Recruiting
Asthma registry that helps researchers learn about asthma
This study enrolls people in specific cities to collect health information that helps researchers better understand asthma and how to recruit future studies. It may help by improving knowledge about asthma types and care in real-world settings.
Chicago, IllinoisAges Any age - NCT00004317RecruitingPhase 4
Treating Congenital Toxoplasmosis With Three Medications
This study tests a combination of three medications (pyrimethamine, sulfadiazine, and leucovorin) to treat toxoplasmosis—a parasitic infection passed from mother to baby during pregnancy. The goal is to see if early treatment prevents serious complications in infected infants.
Chicago, IllinoisAges Any age - NCT06504160RecruitingPhase 1
Testing a bacteria cream for eczema (TIME-2)
This study tests whether a cream made from a friendly skin bacteria (Staphylococcus hominis) can help treat eczema. Eligible participants will apply the cream to eczema patches on their arms, legs, or trunk for several weeks.
Chicago, IllinoisAges 6 years+ - NCT06456541Recruiting
Testing a new infant formula for children with cow's milk allergy
This study tests a new formula designed for children diagnosed with cow's milk allergy. It evaluates whether the formula is safe and well-tolerated.
Chicago, IllinoisAges 3 months–12 years - NCT06832189RecruitingPhase 1
Testing everolimus and epoetin for liver transplant tolerance
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
Chicago, IllinoisAges 18 years+
Hear when a new Allergy trial opens near Chicago, IL
We’ll email you when one opens near Chicago, IL — at most once a week, no account needed, unsubscribe anytime.
Allergy trials in other cities
Where these studies are running near Chicago
Institutions with a site for the recruiting allergy studies listed above.
- Northwestern University · 11 studies
- Ann & Robert H. Lurie Children's Hospital of Chicago · 9 studies
- University of Chicago · 3 studies
- Rush University Cook County Hospital Clinical Research Site
- Rush University CRS
- Rush University Medical Center
- Swedish Hospital
- University of Illinois
What taking part in a allergy study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting allergy studies in Illinois.
Common questions
- Are there allergy clinical trials near Chicago?
- Yes. We're currently tracking 26 recruiting allergy studies with a site near Chicago, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a allergy study near Chicago?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Chicago to take part?
- Not necessarily. These studies have a site near Chicago, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a allergy trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New allergy studies open near Chicago regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.